Factors affecting the pharmacokinetics and pharmacodynamics of liposomal drugs

References

• Abra, R. M., Hunt, C. A. (1981). Liposome disposition in vivo. III. Dose and vesicle-size effects. Biochim Biophys Acta 666:493–503.
   PubMed Web of Science ®Google Scholar
• Alexis, F., Prindgen, E., Molnar, L. K., Farokhzad, O. C. (2008). Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 5:505–515.
   PubMed Web of Science ®Google Scholar
• Allen, T. M. (1981). A study of phospholipid interaction between high-density lipoproteins and small unilamellar vesicles. Biochim Biophys Acta 640:385–397.
   PubMed Web of Science ®Google Scholar
• Allen, T. M., Cheng, W. W., Hare, J. I., Laginha, K. M. (2006). Pharmacokinetics and pharmacodynamics of lipidic nano-particles in cancer. Anticancer Agents Med Chem 6:513–523.
   PubMedGoogle Scholar
• Allen, T. M., Hansen, C. (1991). Pharmacokinetics of stealth versus conventional liposomes: effect of dose. Biochim Biophys Acta 1068:133–141.
   PubMed Web of Science ®Google Scholar
• Allen, T. M., Smuckler, E. A. (1985). Liver pathology accompanying chronic liposome administration in mouse. Res Commun Chem Pathol Pharmacol 50:281–290.
   PubMedGoogle Scholar
• Amantea, M. A., Forrest, A., Northfelt, D. W., Mamelok, R. (1997). Population pharmacokinetics and pharmacodynamics of pegylated liposomal doxorubicin in patients with AIDS-related Kaposi’s sarcoma. Clin Pharmacol Ther 61:301–311.
   PubMed Web of Science ®Google Scholar
• Banerjee, J., Hanson, A. J., Gadam, B., Elegbede, A. I., Tobwala, S., Ganguly, B., et al. (2009). Release of liposomal contents by cell-secreted matrix metalloproteinase-9. Bioconjug Chem 20:1332–1339.
   PubMed Web of Science ®Google Scholar
• Batist, G., Barton, J., Chaikin, P., Swenson, C., Welles, L. (2002). Myocet (liposome-encapsulated doxorubicin citrate): a new approach in breast cancer therapy. Expert Opin Pharmacother 3:1739–1751.
   PubMedGoogle Scholar
• Berry, G., Billingham, M., Alderman, E., Richardson, P., Torti, F., Lum, B., et al. (1998). The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi’s sarcoma patients treated with pegylated liposomal doxorubicin. Ann Oncol 9:711–716.
   PubMed Web of Science ®Google Scholar
• Booser, D. J., Esteva, F. J., Rivera, E., Valero, V., Esparza-Guerra, L., Priebe, W., et al. (2002). Phase II study of liposomal annamycin in the treatment of doxorubicin-resistant breast cancer. Cancer Chemother Pharmacol 50:6–8.
   PubMed Web of Science ®Google Scholar
• Campbell, R. B., Fukumura, D., Brown, E. B., Mazzola, L. M., Izumi, Y., Jain, R. K., et al. (2002). Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors. Cancer Res 62:6831–6836.
   PubMed Web of Science ®Google Scholar
• Campbell, R. B., Ying, B., Kuesters, G. M., Hemphill, R. (2009). Fighting cancer: from the bench to bedside using second generation cationic liposomal therapeutics. J Pharm Sci 98:411–429.
   PubMed Web of Science ®Google Scholar
• Chang, D. K., Lin, C. T., Wu, C. H., Wu, H. C. (2009). A novel peptide enhances therapeutic efficacy of liposomal anti-cancer drugs in mice models of human lung cancer. PLoS One 4: e4171.
   Web of Science ®Google Scholar
• Charrois, G. J., Allen, T. M. (2003). Multiple injections of pegylated liposomal doxorubicin: pharmacokinetics and therapeutic activity. J Pharmacol Exp Ther 306:1058–1067.
   PubMed Web of Science ®Google Scholar
• Charrois, G. J., Allen, T. M. (2003). Rate of biodistribution of STEALTH liposomes to tumor and skin: influence of liposome diameter and implications for toxicity and therapeutic activity. Biochim Biophys Acta 1609:102–108.
   PubMed Web of Science ®Google Scholar
• Chonn, A., Semple, S. C., Cullis, P. R. (1992). Association of blood proteins with large unilamellar liposomes in vivo. Relation to circulation lifetimes. J Biol Chem 267:18759–18765.
   PubMed Web of Science ®Google Scholar
• Clemons, K. V., Stevens, D. A. (1998). Comparison of fungizone, amphotec, ambisome, and abelcet for treatment of systemic murine cryptococcosis. Antimicrob Agent Chemother 42:899–902
   PubMed Web of Science ®Google Scholar
• Conwell, C. C., Huang, L. (2005). Recent advances in non-viral gene delivery. Adv Genet 53PA:1–18.
   PubMedGoogle Scholar
• Cullis, P. R., Chonn, A., Semple, S. C. (1998). Interactions of liposomes and lipid-based carrier systems with blood proteins: relation to clearance behaviour in vivo. Adv Drug Deliv Rev 32:3–17.
   PubMed Web of Science ®Google Scholar
• Dark, G. G., Calvert, A. H., Grimshaw, R., Poole, C., Swenerton, K., Kaye, S., et al. (2005). Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials group. J Clin Oncol 23:1859–1866.
   PubMed Web of Science ®Google Scholar
• Davis, S. C., Szoka, F. C. Jr (1998). Cholesterol phosphate derivatives-synthesis and incorporation into a phosphatase and calcium-sensitive triggered release liposome. Bioconjug Chem 9:783–792.
   PubMed Web of Science ®Google Scholar
• Dokka, S., Toledo, D., Shi, X., Castranova, V., Rojanasakul, Y. (2000). Oxygen radical-mediated pulmonary toxicity induced by some cationic liposomes. Pharm Res 17:521–525.
   PubMed Web of Science ®Google Scholar
• Dos Santos, N., Mayer, L. D., Abraham, S. A., Gallagher, R. C., Cox, K. A., Tardi, P. G., et al. (2002). Improved retention of idarubicin after intravenous injection obtained for cholesterol-free liposomes. Biochim Biophys Acta 1561:188–201.
   PubMed Web of Science ®Google Scholar
• Dromi, S., Frenkel, V., Luk, A., Traughber, B., Angstadt, M., Bur, M., et al. (2007). Pulsed-high intensity focused ultrasound and low temperature-sensitive liposomes for enhanced targeted drug delivery and antitumor effect. Clin Cancer Res 13:2722–2727.
   PubMed Web of Science ®Google Scholar
• Drummond, D. C., Meyer, O., Hong, K., Kirpotin, D. B., Papahadjopoulos, D. (1999). Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 51:691–743.
   PubMed Web of Science ®Google Scholar
• Drummond, D. C., Noble, C. O., Guo, Z., Hayes, M. E., Connolly-Ingram, C., Gabriel, B. S., et al. (2010). Development of a highly stable and targetable nanoliposomal formulation of topotecan. J Control Release 141:13–21.
   PubMed Web of Science ®Google Scholar
• Drummond, D. C., Noble, C. O., Hayes, M. E., Park, J. W., Kirpotin, D. B. (2008). Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development. J Pharm Sci 97:4696–4740.
   PubMed Web of Science ®Google Scholar
• Duffaud, F., Borner, M., Chollet, P., Vermorken, J. B., Bloch, J., Degardin, M., et al. (2004). Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck. An EORTC New Drug Development Group study. Eur J Cancer 40:2748–2752.
   PubMed Web of Science ®Google Scholar
• Eavarone, D. A., Yu, X., Bellamkonda, R. V. (2000). Targeted drug delivery to C6 glioma by transferrin-coupled liposomes. J Biomed Mater Res 51:10–14.
   PubMed Web of Science ®Google Scholar
• Ellens, H., Morselt, H. W., Dontje, B. H., Kalicharan, D., Hulstaert, C. E., Scherphof, G. L. (1983). Effects of liposome dose and the presence of lymphosarcoma cells on blood clearance and tissue distribution of large unilamellar liposomes in mice. Cancer Res 43:2927–2934.
   PubMed Web of Science ®Google Scholar
• Epstein-Barash, H., Gutman, D., Markovsky, E., Mishan-Eisenberg, G., Koroukhov, N., Szebeni, J., et al. (2010). Physicochemical parameters affecting liposomal bisphosphonates bioactivity for restenosis therapy: internalization, cell inhibition, activation of cytokines and complement, and mechanism of cell death. J Control Release 146:182–195.
   PubMed Web of Science ®Google Scholar
• Ewer, M. S., Martin, F. J., Henderson, C., Shapiro, C. L., Benjamin, R. S., Gabizon, A. A. (2004). Cardiac safety of liposomal anthracyclines. Semin Oncol 31:161–181.
   PubMed Web of Science ®Google Scholar
• Fassas, A., Anagnostopoulos, A. (2005). The use of liposomal daunorubicin (DaunoXome) in acute myeloid leukemia. Leuk Lymphoma 46:795–802.
   PubMed Web of Science ®Google Scholar
• Federman, N., Denny, C. T. (2010). Targeting liposomes toward novel pediatric anticancer therapeutics. Pediatr Res 67:514–519.
   PubMed Web of Science ®Google Scholar
• Fedier, A., Poyet, C., Perucchini, D., Boulikas, T., Fink, D. (2006). MLH1-deficient tumor cells are resistant to lipoplatin, but retain sensitivity to lipoxal. Anticancer Drugs 17:315–323.
   PubMed Web of Science ®Google Scholar
• Felman, E. J., Lancet, J. E., Kolitz, J. E., Ritchie, E. K., Roboz, G. J., List, A. F., et al. (2011). First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. J Clin Oncol 29:979–985.
   PubMed Web of Science ®Google Scholar
• Fujita, T. (1974). A scanning electron microscope study of the human spleen. Arch Histol Jpn 37:187–216.
   PubMedGoogle Scholar
• Gabizon, A. A., Barenholz, Y., Bialer, M. (1993). Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid: pharmacokinetic studies in rodents and dogs. Pharm Res 10:703–708.
   PubMed Web of Science ®Google Scholar
• Gabizon, A., Catane, R., Uziely, B., Kaufman, B., Safra, T., Cohen, R., et al. (1994). Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 54:987–992.
   PubMed Web of Science ®Google Scholar
• Gabizon, A., Goren, D., Cohen, R., Barenholz, Y. (1998). Development of liposomal anthracyclines: from basics to clinical applications. J Control Release 53:275–279.
   PubMed Web of Science ®Google Scholar
• Gabizon, A., Isacson, R., Rosengarten, O., Tzemach, D., Shmeeda, H., Sapir, R. (2008). An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin. Cancer Chemother Pharmacol 61:695–702.
   PubMed Web of Science ®Google Scholar
• Gabizon, A., Shmeeda, H., Barenholz, Y. (2003). Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies. Clin Pharmacokinet 42:419–436.
   PubMed Web of Science ®Google Scholar
• Gabizon, A., Tzemach, D., Gorin, J., Mak, L., Amitay, Y., Shmeeda, H., et al. (2010). Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models. Cancer Chemother Pharmacol 66:43–52.
   PubMed Web of Science ®Google Scholar
• Gabizon, A., Tzemach, D., Mak, L., Bronstein, M., Horowitz, A. T. (2002). Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models. J Drug Target 10:539–548.
   PubMed Web of Science ®Google Scholar
• Giles, F. J., Tallman, M. S., Garcia-Manero, G., Cortes, J. E., Thomas, D. A., Wierda, W. G., et al. (2004). Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia. Cancer 100:1449–1458.
   PubMed Web of Science ®Google Scholar
• Gregoriadis, G., Senior, J. (1982). Control of fate and behaviour of liposomes in vivo. Prog Clin Biol Res 102:263–279.
   PubMedGoogle Scholar
• Hassan, M., Nilsson, C., Hassan, Z., Gungor, T., Aschan, J., Winiarski, J., et al. (2002). A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation: 500 mg/m(2) as a optimal total dose for conditioning. Bone Marrow Transplant 30:833–841.
   PubMed Web of Science ®Google Scholar
• Hempel, G., Reinhardt, D., Creutzig, U., Boos, J. (2003). Population pharmacokinetics of liposomal daunorubicin in children. Br J Clin Pharmacol 56:370–377.
   PubMed Web of Science ®Google Scholar
• Hong, Y., Shaw, P. J., Nath, C. E., Yadav, S. P., Stephen, K. R., Earl, J. W., Mclachlan, A. J. (2006). Population pharmacokinetics of liposomal amphotericin B in pediatric patients with malignant diseases. Antimicrob Agents Chemother 50:935–942.
   PubMed Web of Science ®Google Scholar
• Hubert, A., Lyass, O., Pode, D., Gabizon, A. (2000). Doxil (Caelyx): an exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer. Anticancer Drugs 11:123–127.
   PubMed Web of Science ®Google Scholar
• Igarashi, E. (2008). Factors affecting toxicity and efficacy of polymeric nanomedicines. Toxicol Appl Pharmacol 229:121–34.
   PubMed Web of Science ®Google Scholar
• Janoff, A. S., Boni, L. T., Popescu, M. C., Minchey, S. R., Cullis, P. R., Madden, T. D., et al. (1988). Unusual lipid structures selectively reduce the toxicity of amphotericin B. Proc Natl Acad Sci U S A 85:6122–6126.
   PubMed Web of Science ®Google Scholar
• Jones, S. F., Zamboni, W. C., Burris, H. A., III, Chan, E., Infante, J. R., Keedy, V., et al. (2009). Phase I and pharmacokinetic (PK) study of IHL-305 (pegylated liposomal irinotecan) in patients with advanced solid tumors. Presented at the 45th Annual Meeting of the American Society of Clinical Oncology at Orlando, Florida, USA, June 1, 2009.
   Google Scholar
• Kobayashi, T., Ishida, T., Okada, Y., Ise, S., Harashima, H., Kiwada, H. (2007). Effect of transferrin receptor-targeted liposomal doxorubicin in P-glycoprotein-mediated drug resistant tumor cells. Int J Pharm 329:94–102.
   PubMed Web of Science ®Google Scholar
• Krown, S. E., Northfelt, D. W., Osoba, D., Stewart, J. S. (2004). Use of liposomal anthracyclines in Kaposi’s sarcoma. Semin Oncol 31:36–52.
   PubMed Web of Science ®Google Scholar
• La-Beck, N. M., Wu, H., Infante, J. R., Jones, S. F., Burris, H. A., III, Keedy, V. L., et al. (2010). The evaluation of gender on the pharmacokinetics (PK) of pegylated liposomal anticancer agents. Presented at the 2010 American Society of Clinical Oncology Annual Meeting. J Clin Oncol 28(Suppl.): e13003.
   Google Scholar
• La-Beck, N. M., Zamboni, B. A., Gabizon, A., Schmeeda, H., Amanta, M., Gehrig, P. A., et al. (2012). Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients. Cancer Chemother Pharmacol 69:43–50.
   PubMed Web of Science ®Google Scholar
• Laginha, K., Mumbengegwi, D., Allen, T. (2005). Liposomes targeted via two different antibodies: assay, B-cell binding, and cytotoxicity. Biochim Biophys Acta 1711:25–32.
   PubMed Web of Science ®Google Scholar
• Laniado-Laborin, R., Cabrales-Vargas, M. N. (2009). Amphotericin B: side effects and toxicity. Rev Iberoam Micol 26:223–227.
   PubMed Web of Science ®Google Scholar
• Lenaerts. V., Couvreur, P., Christiaens-Lehy, D., Joiris, E., Roland, M., Rollman, B., et al. (1984). Degradation of poly (isobutylcyanocrylate) nanoparticles. Biomaterials 5:65–68.
   PubMed Web of Science ®Google Scholar
• Li, S. D., Huang, L. (2008). Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm 5:496–504.
   PubMed Web of Science ®Google Scholar
• Lindner, L. H., Eichhorn, M. E., Eibl, H., Teichert, N., Schmitt-Sody, M., Issels, R. D., Dellian, M. (2004). Novel temperature-sensitive liposomes with prolonged circulation time. Clin Cancer Res 10:2168–2178.
   PubMed Web of Science ®Google Scholar
• Lindner, L. H., Hossann, M. (2010). Factors affecting drug release from liposomes. Curr Opin Drug Discov Devel 13:111–123.
   PubMed Web of Science ®Google Scholar
• Liu, D., Mori, A., Huang, L. (1992). Role of liposome size and RES blockade in controlling biodistribution and tumor uptake of GM1-containing liposomes. Biochim Biophys Acta 1104:95–101.
   PubMed Web of Science ®Google Scholar
• Lyass, O., Hubert, A., Gabizon, A. A. (2001). Phase I study of doxil-cisplatin combination chemotherapy in patients with advanced malignancies. Clin Cancer Res 7:3040–3046.
   PubMed Web of Science ®Google Scholar
• Lyass, O., Uziely, B., Beb-Yosef, R., Tzemach, D., Hsdhing, N. I., Lotem, M., et al. (2000). Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 89:1037–1047.
   PubMed Web of Science ®Google Scholar
• Maeda, H., Bharate, G. Y., Daruwalla, J. (2009). Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur J Pharm Biopharm 71:409–419.
   PubMed Web of Science ®Google Scholar
• Markman, M., Gordon, A. N., Mcquire, W. P., Muggia, F. M. (2004). Liposomal anthracycline treatment for ovarian cancer. Semin Oncol 31:91–105.
   PubMed Web of Science ®Google Scholar
• Meers, P. (2001). Enzyme-activated targeting of liposomes. Adv Drug Deliv Rev 53:265–272.
   PubMed Web of Science ®Google Scholar
• Metselaar, J. M., Bruin, P., De Boer, L. W., De Vringer, T., Snel, C., Oussoren, C., et al. (2003). A novel family of L-amino acid-based biodegradable polymer-lipid conjugates for the development of long-circulating liposomes with effective drug-targeting capacity. Bioconjug Chem 14:1156–1164.
   PubMed Web of Science ®Google Scholar
• Nardin, A., Lefebvre, M. L., Labroquere, K., Faure, O., Abastado, J. P. (2006). Liposomal muramyl tripeptide phosphatidylethanolamine: targeting and activating macrophages for adjuvant treatment of osteosarcoma. Curr Cancer Drug Targets 6:123–133.
   PubMed Web of Science ®Google Scholar
• Needham, D., Anyarambhatla, G., Kong, G., Dewhirst, M. W. (2000). A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model. Cancer Res 60:1197–1201.
   PubMed Web of Science ®Google Scholar
• Newman, M. S., Colbern, G. T., Working, P. K., Engbers, C., Amantea, M. A. (1999). Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice. Cancer Chemother Pharmacol 43:1–7.
   PubMed Web of Science ®Google Scholar
• Nicoletto, M. O., Bertorelle, R., Borgato, L., De Salvo, G. L., Artioli, G., Lombardi, G., et al. (2009). Family history of cancer rather than p53 status predicts efficacy of pegylated liposomal doxorubicin and oxaliplatin in relapsed ovarian cancer. Int J Gynecol Cancer 19:1022–1028.
   PubMed Web of Science ®Google Scholar
• Niu, M. M., Lu, Y., Hovgaard, L., Wu, W. (2011). Liposomes containing glycocholate as potential oral insulin delivery systems: preparation, in vitro characterization, and improved protection against enzymatic degradation. Int J Nanomedicine 6:1155–1166.
   PubMed Web of Science ®Google Scholar
• Noble, C. O., Kirpotin, D. B., Hayes, M. E., Mamot, C., Hong, K., Park, J. W., et al. (2004). Development of ligand-targeted liposomes for cancer therapy. Expert Opin Ther Targets 8:335–353.
   PubMed Web of Science ®Google Scholar
• Noguchi, Y., Wu, J., Duncan, R., Strohalm, J., Ulbrich, K., Akaike, T., et al. (1998). Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues. Jpn J Cancer Res 89:307–314.
   PubMedGoogle Scholar
• Northfelt, D. W., Martin, F. J., Working, P. (1996). Doxorubicin encapsulated in liposomes containing surface-bound polyethyleneglycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi’s sarcoma. J Clin Pharmcol 36:55–63.
   PubMed Web of Science ®Google Scholar
• Oja, C. D., Semple, S. C., Chonn, A., Cullis, P. R. (1996). Influence of dose on liposome clearance: critical role of blood proteins. Biochim Biophys Acta 1281:31–37.
   PubMed Web of Science ®Google Scholar
• Paliwal, S. R., Paliwal, R., Mishra, N., Mehta, A., Vyas, S. P. (2010). A novel cancer targeting approach based on estrone anchored stealth liposome for site-specific breast cancer therapy. Curr Cancer Drug Targets 10:343–353.
   PubMed Web of Science ®Google Scholar
• Papahadjopoulos, D., Allen, T. M., Gabizon, A., Mayhew, E., Matthay, K., Huang, S. K., et al. (1991). Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci U S A 88:11460–11464.
   PubMed Web of Science ®Google Scholar
• Park, J. W., Kirpotin, D. B., Hong, K., Shalaby, R., Shao, Y., Nielsen, U. B., et al. (2001). Tumor targeting using anti-her2 immunoliposomes. J Control Release 74:95–113.
   PubMed Web of Science ®Google Scholar
• Phuphanich, S., Maria, B., Braeckman, R., Chamberlain, M. (2007). A pharmacokinetic study of intra-CSF administered encapsulated cytarabine (DepoCyt) for the treatment of neoplastic meningitis in patients with leukemia, lymphoma, or solid tumors as part of a phase III study. J Neurooncol 81:201–208.
   PubMed Web of Science ®Google Scholar
• Pisarik, L., Joly, V., Jullien, S., Carbon, C., Yeni, P. (1990). Reduction of free amphotericin B acute toxicity in mice after intravenous administration of empty liposomes. J Infect Dis 161:1042–1044.
   PubMed Web of Science ®Google Scholar
• Ravaioli, A., Papi, M., Pasquini, E., Marangolo, M., Runas, B., Fantini, M., et al. (2009). Lipoplatin monotherapy: a phase II trial of second-line treatment of metastatic non-small-cell lung cancer. J Chemother 21:86–90.
   PubMed Web of Science ®Google Scholar
• Rose, P. G. (2005). Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer. Oncologist 10:205–214.
   PubMed Web of Science ®Google Scholar
• Rudin, C. M., Marshall, J. L., Huang, C. H., Kindler, H. L., Zhang, C., Kumar, D., et al. (2004). Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I study. Clin Cancer Res 10:7244–7251.
   PubMed Web of Science ®Google Scholar
• Samad, A., Sultana, Y., Aqil, M. (2007). Liposomal drug delivery systems: an update review. Curr Drug Deliv 4:297–305.
   PubMedGoogle Scholar
• Sangha, R., Butts, C. (2007). L-BLP25: a peptide vaccine strategy in non small cell lung cancer. Clin Cancer Res 13:s4652–s4654.
   PubMed Web of Science ®Google Scholar
• Sapra, P., Allen, T. M. (2003). Ligand-targeted liposomal anticancer drugs. Prog Lipid Res 42:439–462.
   PubMed Web of Science ®Google Scholar
• Scheule, R. K., St., George, J. A., Bagley, R. G., Marshall, J., Kaplan, J. M., Akita, G. Y., et al. (1997). Basis of pulmonary toxicity associated with cationic lipid-mediated gene transfer to the mammalian lung. Hum Gene Ther 8:689–707.
   PubMed Web of Science ®Google Scholar
• Schmitt-Sody, M., Strieth, S., Krasnici, S., Sauer, B., Schulze, B., Teifel, M., et al. (2003). Neovascular targeting therapy: paclitaxel encapsulated in cationic liposomes improves antitumoral efficacy. Clin Cancer Res 9:2335–2341.
   PubMed Web of Science ®Google Scholar
• Schroeder, A., Kost, J., Barenholz, Y. (2009). Ultrasound, liposomes, and drug delivery: principles for using ultrasound to control the release of drugs from liposomes. Chem Phys Lipids 162:1–16.
   PubMed Web of Science ®Google Scholar
• Seetharamu, N., Kim, E., Hochster, H., Martin, F., Muggia, F. (2010). Phase II study of liposomal cisplatin (SPI-77) in platinum-sensitive recurrences of ovarian cancer. Anticancer Res 30:541–545.
   PubMed Web of Science ®Google Scholar
• Sidone B. J., Edwards, R. P., Zamboni, B. A. (2007). Evaluation of body surface area (BSA) based dosing, age, and body composition as factors affecting the pharmacokinetics (PK) variability of PEGYLATED liposomal doxorubicin (Doxil). Presented at the 2007 AACR-NCI-EORTC conference, San Francisco, California, USA, October 22–26, 2007.
   Google Scholar
• Siegal, T., Horowitz, A., Gabizon, A. (1995). Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy. J Neurosurg 83:1029–1037.
   PubMed Web of Science ®Google Scholar
• Shmeeda, H., Tzemach, D., Mak, L., Gabizon, A. (2009). Her2-targeted pegylated liposomal doxorubicin: retention of target-specific binding and cytotoxicity after in vivo passage. J Control Release 136:155–160.
   PubMed Web of Science ®Google Scholar
• Soni, V., Kohli, D. V., Jain, S. K. (2008). Transferrin-conjugated liposomal system for improved delivery of 5-fluorouracil to brain. J Drug Target 16:73–78.
   PubMed Web of Science ®Google Scholar
• Song, G., Wu, H., La-Beck, N., Zamboni, B. A., Strychor, S., Zamboni, W. C. (2009). Effect of gender on pharmacokinetic disposition of pegylated liposomal CKD-602 (S-CKD602) and optisomal topotecan (TLI) in rats [poster presentation]. Presented at the 2009 American Association of Cancer Research Annual Meeting at Washington, DC. Abstract #3700.
   Google Scholar
• Spira, J., Plyushch, O. P., Andreeva, T. A., Andreev, Y. (2006). Prolonged bleeding-free period following prophylactic infusion of recombinant factor VIII reconstituted with pegylated liposomes. Blood 108:3668–3673.
   PubMed Web of Science ®Google Scholar
• Stathopoulos, G. P., Boulikas, T., Kourvetaris, A., Stathopoulos, J. (2006). Liposomal oxaliplatin in the treatment of advanced cancer: a phase I study. Anticancer Res 26:1489–1493.
   PubMed Web of Science ®Google Scholar
• Tailor, T. D., Hanna, G., Yarmolenko, P. S., Dreher, M. R., Betof, A. S., Nixon, A. B., et al. (2010). Effect of pazopanib on tumor microenvironment and liposome delivery. Mol Cancer Ther 9:1798–1808.
   PubMed Web of Science ®Google Scholar
• Takeuchi, H., Kojima, H., Yamamoto, H., Kawashima, Y. (2001). Evaluation of circulation profiles of liposomes coated with hydrophilic polymers having different molecular weight in rats. J Control Release 75:83–91.
   PubMed Web of Science ®Google Scholar
• Torchillin, V. P., Levchenko, T. S., Whiteman, K. R., Yaroslavov, A. A., Tsatsakis, A. M., Rizos, A. K., et al. (2001). Amphiphilic poly-N-vinylpyrrolidones:synthesis, properties, and liposome surface modification. Biomaterials 22:3035–3044.
   PubMed Web of Science ®Google Scholar
• Torchilin, V. P. (2005). Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 4:145–160.
   PubMed Web of Science ®Google Scholar
• Veal, G. J., Griffin, M. J., Price, E., Parry, A., Dick, G. S., Little, M. A., et al. (2001). A phase I study in paediatric patients to evaluate the safety and pharmacokinetics of SPI-077, a liposome encapsulated formulation of cisplatin. Br J Cancer 84:1029–1035.
   PubMed Web of Science ®Google Scholar
• Veerareddy, P. R., Vobalaboina, V. (2004). Lipid-based formulations of amphotericin B. Drugs Today (Barc) 40:133–145.
   PubMed Web of Science ®Google Scholar
• Wang, J., Sui, M., Fan, W. (2010). Nanoparticles for tumor targeted therapies and their pharmacokinetics. Curr Drug Metab 11:129–141.
   PubMed Web of Science ®Google Scholar
• Whiteman, K. R., Subr, V., Ulbrich, K., Torchillin, V. P. (2001). Poly(HPMA)-coated liposomes demonstrate prolonged circulation in mice. J Liposome Res 11:153–164.
   PubMed Web of Science ®Google Scholar
• Woodle, M. C., Lasic, D. D. (1992). Sterically stabilized liposomes. Biochim Biophys Acta 1113:171–199.
   PubMed Web of Science ®Google Scholar
• Working, P. K., Dayan, A. D. (1996). Pharmacological-toxicological expert report. CAELYX. (Stealth liposomal doxorubicin HCl). Hum Exp Toxicol 15:751–785.
   PubMed Web of Science ®Google Scholar
• Wu, H., Ramanathan, R. K., Zamboni, B. A., Strychor, S., Ramalingam, S., Edwards, R. P., et al. (2011). Population pharmacokinetics of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies. J Clin Pharmacol Jan 13. [Epub ahead of print]
   Web of Science ®Google Scholar
• Wu, H., Infante, J. R., Jones, S. F. III, Burris, H. A., Chan, E., Keedy, V. L., et al. (2009). Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors. Abstract C127. In 2009 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
   Google Scholar
• Xiong, X. B., Huang, Y., Lu, W. L., Zhang, X., Zhang, H., Nagai, T., et al. (2005). Intracellular delivery of doxorubicin with RGD-modified sterically stabilized liposomes for an improved antitumor efficacy: in vitro and in vivo. J Pharm Sci 94:1782–1793.
   PubMed Web of Science ®Google Scholar
• Yoo, G. H., Hung, M. C., Lopez-Berestein, G., Lafollette, S., Ensley, J. F., Carey, M., et al. (2001). Phase I trial of intratumoral liposome E1A gene therapy in patients with recurrent breast and head and neck cancer. Clin Cancer Res 7:1237–1245.
   PubMed Web of Science ®Google Scholar
• Yuan, F., Dellian, M., Fukumura, D., Leunig, M., Berk, D. A., Torchilin, V. P., et al. (1995). Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 55:3752–3726.
   PubMed Web of Science ®Google Scholar
• Yurkovetskiy, A. V., Hiller, A., Syed, S., Yin, M., Lu, X. M., Fischman, A. J., et al. (2004). Synthesis of a macromolecular camptothecin conjugate with dual phase drug release. Mol Pharm 1:375–382.
   PubMed Web of Science ®Google Scholar
• Zamboni, W. C. (2005). Liposomal, nanoparticle, and conjugated formulations of anticancer agents. Clin Cancer Res 11:8230–8234.
   PubMed Web of Science ®Google Scholar
• Zamboni, W. C., Gervais, A. C., Egorin, M. J., Schellens, J. H., Zuhowski, E. G., Pluim, D., et al. (2004). Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma. Cancer Chemother Pharmacol 53:329–336.
   PubMed Web of Science ®Google Scholar
• Zamboni, W. C., Maruca, L. J., Strychor, S., Zamboni, B. A., Ramalingam, S., Edwards, R. P., et al. (2011). Bidirectional pharmacodynamic interaction between pegylated liposomal CKD-602 (S-CKD602) and monocytes in patients with refractory solid tumors. J Liposome Res 21:158–165.
   PubMed Web of Science ®Google Scholar
• Zamboni, W. C., Eiseman, J. E., Strychor, S., Rice, P. M., Joseph, E., Potter, D. M., et al. (2006). Relationship between the plasma and tumor disposition of STEALTH liposomal CKD-602 and macrophages/dendritic cells (MDC) in mice bearing human tumor xenografts. Proc AACR 47:1280.
   Google Scholar
• Zamboni, W. C., Edwards, R. P., Mountz, J. M. (2007). NSTI Nanotechnology Conference. The development of liposomal and nanoparticle anticancer agents: Methods to evaluate the encapsulated and released drug in plasma and tumor and phenotypic probes for the pharmacokinetic and pharmacodynamic disposition.
   Google Scholar
• Zamboni, W. C., Ramalingam, S., Friedland, D. M., Edwards, R. P., Stoller, R. G., Strychor, S., et al. (2009a). Phase I and pharmacokinetic study of pegylated liposomal CKD-602 in patients with advanced malignancies. Clin Cancer Res 15:1466–1472.
   PubMed Web of Science ®Google Scholar
• Zamboni, W. C., Strychor, S., Maruca, L., Ramaligam, S., Zamboni, B. A., Wu, H., et al. (2009b). Pharmacikinetic study of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies. Clin Pharmacol Ther 86:519–526.
   PubMed Web of Science ®Google Scholar